NEWARK, DE | The solid oral dosage PROTAC degrader formulations market was valued at USD 130 million in 2025 and is projected to reach USD 3.49 billion by 2036, expanding at a robust CAGR of 35.40%. With sales expected to reach USD 170 million in 2026, the market is gaining traction as biopharmaceutical innovators shift toward oral delivery formats for targeted protein...